Analysis of <i>KRAS</i> / <i>NRAS</i> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Peeters, Marc; S. Oliner, Kelly; Price, Timothy; Cervantes, Andrés; Sobrero, Alberto; Ducreux, Michel; Hotko, Yevhen; André, Thierry; Chan, Emily; Lordick, Florian; J.A. Punt, Cornelis; Strickland, Andrew; Wilson, G.; Ciuleanu, Tudor–Eliade; Roman, Laslo; Van Cutsem, Eric; He, Pei; Yu, Hua; Koukakis, Reija; Terwey, Jan-Henrik; Scott Jung, A.; Sidhu, Roger; D. Patterson, Scott

doi:10.1158/1078-0432.ccr-15-0526

Public

Analysis of KRAS / NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Published in Clinical Cancer Research • Sep 4, 2015

Authors:

Marc Peeters

Kelly S. Oliner

Timothy Price

Abstract

PURPOSE: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in...

Subject

Panitumumab

FOLFIRI

KRAS

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!